Results 301 to 310 of about 1,442,988 (353)

Bispecific antibodies for delivery into the brain

Current Opinion in Chemical Biology, 2013
The blood-brain barrier (BBB) is a formidable obstacle preventing drug delivery to the brain, particularly for large protein therapeutics. The utilization of endogenous brain endothelial transport pathways, however, represents a promising approach to cross the cellular barrier through receptor-mediated transcytosis.
Ryan J. Watts, Mark S. Dennis
openaire   +3 more sources

A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies

Science Translational Medicine, 2020
CD28 bispecific antibodies are well tolerated and enhance the antitumor efficacy of CD3 bispecifics as a potential off-the-shelf antibody therapy. Double trouble for tumors Bispecific antibodies, which have one arm that binds to a cancer cell antigen and
D. Skokos, Janelle C. Waite, Lauric Haber, Alison Crawford, Aynur Hermann, Erica Ullman, Rabih Slim, Stephen Godin, D. Ajithdoss, Xuan Ye, Bei Wang, Qi Wu, Ilyssa Ramos, Arpita Pawashe, Lauren Canova, Kristin Vazzana, Priyanka Ram, E. Herlihy, Hassan Ahmed, E. Oswald, Jacquelynn Golubov, P. Poon, L. Havel, D. Chiu, Miguel Lazo, Kathleen Provoncha, Kevin Yu, Julie Kim, Jacqueline J Warsaw, Nicole Stokes Oristian, C. Siao, Drew Dudgeon, Tammy Huang, Terra Potocky, Joel Martin, D. MacDonald, A. Oyejide, A. Rafique, W. Poueymirou, J. Kirshner, Eric J. Smith, W. Olson, John C. Lin, G. Thurston, M. Sleeman, A. Murphy, G. Yancopoulos   +46 more
semanticscholar   +1 more source

Targeting cancer with bispecific antibodies [PDF]

Science, 2021
Bispecific antibodies might provide off-the-shelf immunotherapeutics for treating ...
openaire   +2 more sources

Bispecific antibodies for the treatment of hemophilia A

Expert Opinion on Biological Therapy, 2021
Emicizumab is a bispecific antibody exerting cofactor function of FVIIIa irrespective of the presence of FVIII inhibitors. Long-term data of phase 1/2 and phase 3 studies have been accumulated. Various questions such as indicated patients, ITI, application to PUPs, hemostatic treatment including surgeries, and emicizumab-related morbidity remain to be ...
openaire   +3 more sources

Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy

Science Translational Medicine, 2020
Antibodies cross-linking the CD28 costimulatory pathway and a target antigen on tumors potentiate the effects of checkpoint immunotherapy. Immunotherapies combining forces Although immunotherapy has been achieving increasing prominence in cancer ...
Janelle C. Waite, Bei Wang, Lauric Haber, Aynur Hermann, Erica Ullman, Xuan Ye, Drew Dudgeon, Rabih Slim, D. Ajithdoss, Stephen Godin, Ilyssa Ramos, Qi Wu, E. Oswald, P. Poon, Jacquelynn Golubov, Devon Grote, Jennifer Stella, Arpita Pawashe, Jennifer Finney, E. Herlihy, Hassan Ahmed, V. Kamat, Amanda Dorvilliers, E. Navarro, Jenny Xiao, Julie Kim, S. Yang, Jacqueline J Warsaw, Clarissa Lett, Lauren Canova, Teresa Schulenburg, Randi Foster, P. Krueger, E. Garnova, A. Rafique, R. Babb, Gang Chen, Nicole Stokes Oristian, C. Siao, C. Daly, C. Gurer, Joel Martin, L. Macdonald, D. MacDonald, W. Poueymirou, Eric J. Smith, I. Lowy, G. Thurston, W. Olson, John C. Lin, M. Sleeman, G. Yancopoulos, A. Murphy, D. Skokos   +53 more
semanticscholar   +1 more source

Bispecific antibodies in cancer therapy

Current Opinion in Immunology, 1999
Based upon in vitro and animal studies, a number of Phase I and II clinical trials have been initiated to test whether bispecific antibodies could redirect immune effectors against tumor cells in cancer patients. Recently, results from those trials showed beneficial effects in some patients but it is clear many problems remain to be solved. In addition,
George J. Weiner, David M. Segal, Louis M. Weiner   +2 more
openaire   +2 more sources

Antibody–drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry

Archives of pharmacal research, 2023
Yeji Hong, Su-Min Nam, A. Moon
semanticscholar   +1 more source

Bispecific Antibodies for Thrombolysis

1992
The seach of new methods for treatment of “century deseases” such as cancer or atherosclerosis with associated thrombosis sets up a problem of targeting of biologically active substances to localized areas of organism. The use of bifunctional (chimeric) antibodies (particularly - bifunctional monoclonals - biMoAbs) as means of drug targeting becomes a ...
M. Yu. Matveyev, M. V. Tsybulskaya, S. P. Domogatsky   +2 more
openaire   +2 more sources

Chemical Production of Bispecific Antibodies

2004
This chapter discusses two related methods for creating Fab' x Fab' chemically linked BsAb. Both methods require the generation of purified F(ab')2 fragments of each antibody and use reagents that react with the free thiols generated upon reduction of interheavy chain disulfide bonds of the F(ab')2 fragments. Upon reduction, the resulting Fabs are then
Paul Guptill, Robert F. Graziano
openaire   +3 more sources

T-cell-engaging bispecific antibodies in cancer

The Lancet, 2023
N. Donk, S. Zweegman
semanticscholar   +1 more source